Macrovascular diabetic complications: Clinical characteristics, diagnosis and management;Complicações macrovasculares do diabetes melito: Peculiaridades clínicas, de diagnóstico e manejo

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 53, Issue 6, 2009, Pages 698-708

  Triches, Cristina ^a   Schaan, Beatriz D'Agord ^a   Gross, Jorge Luiz ^a   de Azevedo, Mirela Jobim ^a  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Cardiovascular disease; Coronary artery disease; Diabetes mellitus; Diagnosis; Risk factors; Treatment

Indexed keywords

EID: 70449373435     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/s0004-27302009000600002     Document Type: Article

References (73)

1. Scheffel RS, Bortolanza D, Weber CS, Costa LA, Canani LH, Santos KG, et al. Prevalence of micro and macroangiopatic chronic com-plications and their risk factors in the care of out patients withtype 2 diabetes mellitus. Rev Assoc Med Bras. 2004;50(3): 263-7.
2. Schaan BD, Harzheim E, Gus I. Cardiac risk profile in diabetes mellitusand impaired fasting glucose. Rev Saude Publica. 2004;38(4): 529-36.
3. Quadros AS, Sarmento-Leite R, Bertoluci M, Duro K, Schmidt A, De Lucca G Jr., et al. Angiographic coronary artery disease is as-sociated with progressively higher levels of fasting plasma glucose. Diabetes Res Clin Pract. 2007;75(2): 207-13.
4. Schaan BD, Quadros A, Sarmento-Leite R, Gottschall CA. Diabetes and coronary stent implantation: experience from a referencecenter in interventional cardiology. Arq Bras Endocrinol Metabol.2006;50(1): 38-45.
5. Borch-Johnsen K, Kreiner S. Proteinuria: value as predictor ofcardiovascular mortality in insulin dependent diabetes mellitus. Br Med J (Clin Res Ed). 1987;294(6588): 1651-4.
6. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, otherrisk factors, and 12-yr cardiovascular mortality for men screenedin the Multiple Risk Factor Intervention Trial. Diabetes Care.1993;16(2): 434-44.
7. Stegmayr B, Asplund K. Diabetes as a risk factor for stroke. Apopulation perspective. Diabetologia. 1995;38(9): 1061-8.
8. Canavan RJ, Unwin NC, Kelly WF, Connolly VM. Diabetes- andnondiabetes-related lower extremity amputation incidence be-fore and after the introduction of better organized diabetes footcare: continuous longitudinal monitoring using a standard method. Diabetes Care. 2008;31(3): 459-63.
9. Beck MO, Silveiro SP, Friedman R, Clausell N, Gross JL. Asymptomatic coronary artery disease is associated with cardiac auto-nomic neuropathy and diabetic nephropathy in type 2 diabeticpatients. Diabetes Care. 1999;22(10): 1745-7.
10. Quadros A, Diemer F, Lima T, Abdalla R, Vizotto M, Gottschall CA, et al. Percutaneous coronary intervention in diabetes mellitus: anupdated analysis of medical practice. Arq Bras Endocrinol Meta-bol. 2007;51(2): 327-33.
11. Malmberg K, Ryden L, Hamsten A, Herlitz J, Waldenstrom A, Wedel H. Effects of insulin treatment on cause-specific one-yearmortality and morbidity in diabetic patients with acute myocar-dial infarction. DIGAMI Study Group. Diabetes Insulin-Glucose in Acute Myocardial Infarction. Eur Heart J. 1996;17(9): 1337-44.
12. Tuomilehto J, Rastenyte D, Jousilahti P, Sarti C, Vartiainen E. Diabetes mellitus as a risk factor for death from stroke. Pro-spective study of the middle-aged finnish population. Stroke.1996;27(2): 210-5.
13. Meijer WT, Hoes AW, Rutgers D, Bots ML, Hofman A, Grobbee DE. Peripheral arterial disease in the elderly: The Rotterdam Study. Arterioscler Thromb Vasc Biol. 1998;18(2):185-92.
14. Peripheral arterial disease in people with diabetes. Diabetes Care.2003;26(12): 3333-41.
15. Pickett CA, Jackson JL, Hemann BA, Atwood JE. Carotid bruitsas a prognostic indicator of cardiovascular death and myocardialinfarction: a meta-analysis. Lancet. 2008;371(9624): 1587-94.
16. Standards of medical care in diabetes-2009. Diabetes Care. 2009; 32 Suppl 1:S13-61.
17. Third Report of the National Cholesterol Education Program(NCEP) Expert Panel on Detection, Evaluation, and Treatment ofHigh Blood Cholesterol in Adults (Adult Treatment Panel III) finalreport. Circulation. 2002;106(25): 3143-421.
18. Evans JM, Wang J, Morris AD. Comparison of cardiovascular riskbetween patients with type 2 diabetes and those who had had amyocardial infarction: cross sectional and cohort studies. BMJ. 2002;324(7343): 939-42.
19. Dora JM, Kramer CK, Canani LH. Standards of Medical Care in Diabetes - 2008: response to Hirsch, Inzucchi, and Kirkman. Dia-betes Care 2008;31(5):e44; author reply e45.
20. Stevens RJ, Kothari V, Adler AI, Stratton IM. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci (Lond). 2001;101(6): 671-9.
21. Best LG, Zhang Y, Lee ET, Yeh JL, Cowan L, Palmieri V, et al. C-reactive protein as a predictor of cardiovascular risk in a population with a high prevalence of diabetes: the Strong Heart Study. Circulation. 2005;112(9): 1289-95.
22. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr., Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med.2008;359(21): 2195-207.
23. Saremi A, Nelson RG, Tulloch-Reid M, Hanson RL, Sievers ML,Taylor GW, et al. Periodontal disease and mortality in type 2 diabetes. Diabetes Care. 2005;28(1): 27-32.
24. Effect of intensive blood-glucose control with metformin on com-plications in overweight patients with type 2 diabetes (UKPDS34). UK Prospective Diabetes Study (UKPDS) Group. Lancet.1998;352(9131): 854-65.
25. The Diabetes Control and Complications Trial/Epidemiology ofDiabetes Interventions and Complications (DCCT/EDIC) StudyResearch Group. Intensive Diabetes treatment and cardiovas-cular disease in patients with type 1 diabetes. N Engl J Med.2005;353(25): 2643-53.
26. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-yearfollow-up of intensive glucose control in type 2 diabetes. N EnglJ Med. 2008;359(15): 1577-89.
27. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Pro-spective Diabetes Study Group. BMJ. 1998;317(7160): 703-13.
28. Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med. 2008;359(15): 1565-76.
29. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr., et al. Seventh report of the Joint National Committee onPrevention, Detection, Evaluation, and Treatment of High BloodPressure. Hypertension. 2003;42(6): 1206-52.
30. Kramer CK, Leitao CB, Canani LH, Gross JL. Impact of white-coathypertension on microvascular complications in type 2 diabetes. Diabetes Care. 2008;31(12): 2233-7.
31. Leitao CB, Canani LH, Kramer CK, Boza JC, Pinotti AF, Gross JL. Masked hypertension, urinary albumin excretion rate, andechocardiographic parameters in putatively normotensive type 2diabetic patients. Diabetes Care. 2007;30(5): 1255-60.
32. Leitao CB, Canani LH, Silveiro SP, Gross JL. Ambulatory bloodpressure monitoring and type 2 diabetes mellitus. Arq Bras Car-diol. 2007;89(5):315-21, 347-54.
33. Gross JL, Silveiro SP, Canani LH, Friedman R, Leitao CB, AzevedoMJ. Diabetic nephropathy and cardiac disease. Arq Bras Endocri-nol Metabol. 2007;51(2): 244-56.
34. Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML,Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, andtreatment. Diabetes Care. 2005;28(1): 164-76.
35. Incerti J, Zelmanovitz T, Camargo JL, Gross JL, de Azevedo MJ. Evaluation of tests for microalbuminuria screening in patientswith diabetes. Nephrol Dial Transplant. 2005;20(11): 2402-7.
36. Gross ML, Dikow R, Ritz E. Diabetic nephropathy: recent insightsinto the pathophysiology and the progression of diabetic neph-ropathy. Kidney Int Suppl. 2005(94): 50-3.
37. Deo A, Fogel M, Cowper SE. Nephrogenic systemic fibrosis: a pop-ulation study examining the relationship of disease developmentto gadolinium exposure. Clin J Am Soc Nephrol. 2007;2(2): 264-7.
38. Azevedo MJ, Neto AF, Caramori ML, Beck MO, Moreira JS, Lu-dwig R, et al. Value of diagnostic tools for myocardial ischemia used in routine clinical practice to predict cardiac events in patients with type 2 diabetes mellitus: a prospective study. Arq BrasEndocrinol Metabol. 2006;50(1): 46-52.
39. Snow V, Barry P, Fihn SD, Gibbons RJ, Owens DK, Williams SV, et al. Evaluation of primary care patients with chronic stable angina:guidelines from the American College of Physicians. Ann InternMed. 2004;141(1): 57-64.
40. Bax JJ, Young LH, Frye RL, Bonow RO, Steinberg HO, Barrett EJ. Screening for coronary artery disease in patients with diabetes. Diabetes Care. 2007;30(10): 2729-36.
41. Bax JJ, Inzucchi SE, Bonow RO, Schuijf JD, Freeman MR, BarrettEJ. Cardiac imaging for risk stratification in diabetes. DiabetesCare. 2007;30(5): 1295-304.
42. Wackers FJ, Young LH, Inzucchi SE, Chyun DA, Davey JA, Barrett EJ, et al. Detection of silent myocardial ischemia in asymptomatic dia-betic subjects: the DIAD study. Diabetes Care. 2004;27(8): 1954-61.
43. Snow V, Barry P, Fihn SD, Gibbons RJ, Owens DK, Williams SV, et al. Primary care management of chronic stable angina and as-ymptomatic suspected or known coronary artery disease: a clini-cal practice guideline from the American College of Physicians. Ann Intern Med. 2004;141(7): 562-7.
44. Miller JM, Rochitte CE, Dewey M, Arbab-Zadeh A, Niinuma H,Gottlieb I, et al. Diagnostic performance of coronary angiographyby 64-row CT. N Engl J Med. 2008;359(22): 2324-36.
45. Greenland P, Bonow RO, Brundage BH, Budoff MJ, Eisenberg MJ, Grundy SM, et al. ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American Collegeof Cardiology Foundation Clinical Expert Consensus Task Force(ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography). Circulation. 2007;115(3): 402-26.
46. Kim SH, Hong MK, Park DW, Lee SW, Kim YH, Lee CW, et al. Impactof plaque characteristics analyzed by intravascular ultrasound onlong-term clinical outcomes. Am J Cardiol. 2009;103(9): 1221-6.
47. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovasculardisease with atorvastatin in type 2 diabetes in the CollaborativeAtorvastatin Diabetes Study (CARDS): multicentre randomisedplacebo-controlled trial. Lancet. 2004;364(9435): 685-96.
48. Boule NG, Haddad E, Kenny GP, Wells GA, Sigal RJ. Effects ofexercise on glycemic control and body mass in type 2 diabe-tes mellitus: a meta-analysis of controlled clinical trials. JAMA.2001;286(10): 1218-27.
49. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in pa-tients with type 2 diabetes. N Engl J Med. 2008;358(24): 2560-72.
50. Gerstein HC, Miller ME, Byington RP, Goff DC Jr., Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24): 2545-59.
51. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veteranswith type 2 diabetes. N Engl J Med. 2009;360(2): 129-39.
52. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, et al. Intensive glycemic control and the prevention of car-diovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials. A Position Statement of the American DiabetesAssociation and a Scientific Statement of the American Collegeof Cardiology Foundation and the American Heart Association.Circulation. 2008.
53. Selvin E, Bolen S, Yeh HC, Wiley C, Wilson LM, Marinopoulos SS, et al. Cardiovascular outcomes in trials of oral diabetes medications:a systematic review. Arch Intern Med. 2008;168(19): 2070-80.
54. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycemia in type2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1): 193-203.
55. Gross JL, Friedman R, Silveiro SP. Preventing nephropathy in-duced by contrast medium. N Engl J Med. 2006;354(17):1853-5;author reply 1853-5.
56. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, et al. Thiazolidinedione use, fluid retention, and congestive heart fail-ure: a consensus statement from the American Heart Association andAmerican Diabetes Association. Diabetes Care. 2004;27(1): 256-63.
57. Colwell JA. Aspirin therapy in diabetes. Diabetes Care. 2004;27(Suppl 1): S72-3.
58. Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ.Amplified benefit of clopidogrel versus aspirin in patients withdiabetes mellitus. Am J Cardiol. 2002;90(6): 625-8.
59. A randomised, blinded, trial of clopidogrel versus aspirin in pa-tients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348(9038): 1329-39.
60. Effects of ramipril on cardiovascular and microvascular outcomesin people with diabetes mellitus: results of the HOPE study andMICRO-HOPE substudy. Heart Outcomes Prevention EvaluationStudy Investigators. Lancet. 2000;355(9200): 253-9.
61. Vijan S, Hayward RA. Pharmacologic lipid-lowering therapy intype 2 diabetes mellitus: background paper for the American Col-lege of Physicians. Ann Intern Med. 2004;140(8): 650-8.
62. Malmberg K, Herlitz J, Hjalmarson A, Ryden L. Effects of meto-prolol on mortality and late infarction in diabetics with suspectedacute myocardial infarction. Retrospective data from two largestudies. Eur Heart J. 1989;10(5): 423-8.
63. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI). Circulation. 1997; 96(6): 1761-9.
64. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al. Optimal medical therapy with or without PCI for stablecoronary disease. N Engl J Med. 2007;356(15): 1503-16.
65. Stettler C, Allemann S, Wandel S, Kastrati A, Morice MC, Schomig A, et al. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. BMJ. 2008;337:a1331.
66. Wackers FJ, Chyun DA, Young LH, Heller GV, Iskandrian AE, Davey JA, et al. Resolution of asymptomatic myocardial ischemia in patients with type 2 diabetes in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) study. Diabetes Care. 2007;30(11): 2892-8.
67. Young LH, Wackers FJ, Chyun DA, Davey JA, Barrett EJ, Taillefer R, et al. Cardiac outcomes after screening for asymptomatic coronaryartery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. JAMA. 2009;301(15): 1547-55.
68. Sorajja P, Chareonthaitawee P, Rajagopalan N, Miller TD, Frye RL, Hodge DO, et al. Improved survival in asymptomatic diabetic patients with high-risk SPECT imaging treated with coronary arterybypass grafting. Circulation. 2005; 112(9 Suppl): I311-6.
69. Hlatky MA, Boothroyd DB, Bravata DM, Boersma E, Booth J, Brooks MM, et al. Coronary artery bypass surgery compared withpercutaneous coronary interventions for multivessel disease: acollaborative analysis of individual patient data from ten randomised trials. Lancet. 2009;373(9670): 1190-7.
70. Ezekowitz MD, Levine JA. Preventing stroke in patients with atrialfibrillation. JAMA. 1999;281(19): 1830-5.
71. Barnett HJ, Taylor DW, Eliasziw M, Fox AJ, Ferguson GG, Haynes RB, et al. Benefit of carotid endarterectomy in patients with symp-tomatic moderate or severe stenosis. North American Symptom-atic Carotid Endarterectomy Trial Collaborators. N Engl J Med.1998;339(20): 1415-25.
72. Leng GC, Fowler B, Ernst E. Exercise for intermittent claudication. Cochrane Database of Systematic Reviews (Online: Update Soft-ware) 2004(2): CD000990.
73. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of amultifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580-91.